Olr482 inhibitors represent a fascinating category of chemical compounds that interact specifically with the olfactory receptor 482 (Olr482), a G protein-coupled receptor (GPCR) predominantly expressed in the olfactory system. These inhibitors are designed to modulate the activity of Olr482 by binding to the receptor and altering its conformation, thereby inhibiting its ability to interact with specific odorant molecules. This inhibition is typically achieved through competitive or allosteric mechanisms, where the inhibitor either directly competes with the natural ligand for binding at the active site or induces conformational changes in the receptor that reduce its affinity for the ligand. The structural diversity of Olr482 inhibitors is considerable, with many compounds exhibiting varied chemical scaffolds, including heterocyclic rings, aromatic moieties, and other functional groups that contribute to their binding specificity and affinity.
In terms of chemical properties, Olr482 inhibitors often feature specific pharmacophores that enable their selective interaction with the receptor. These may include hydrogen bond donors and acceptors, hydrophobic pockets, and aromatic stacking interactions, all of which are crucial for the high affinity and selectivity observed in these inhibitors. Moreover, the design and synthesis of Olr482 inhibitors are driven by the need to optimize these interactions, often requiring a detailed understanding of the receptor's three-dimensional structure and the dynamics of its binding pocket. Advanced computational modeling and structure-activity relationship (SAR) studies play a significant role in this process, allowing researchers to predict and enhance the efficacy of these inhibitors. The study of Olr482 inhibitors also involves extensive in vitro assays to characterize their binding kinetics, receptor-ligand interactions, and overall inhibitory potency, providing valuable insights into the molecular mechanisms that govern olfactory signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Activates AMPK, potentially influencing metabolic pathways and proteins associated with them. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple tyrosine kinases, potentially affecting proteins involved in cell signaling and growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase, potentially affecting proteins in leukemia-associated pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted tyrosine kinase inhibitor, potentially influencing proteins involved in angiogenesis and tumor growth. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Modulates autophagy, potentially influencing proteins involved in cellular degradation pathways. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
Activates PPARδ, potentially influencing proteins associated with energy metabolism. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Inhibits BRAF kinase, potentially affecting proteins involved in the MAPK/ERK pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits proteasome, potentially affecting protein degradation and cell cycle regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases, potentially influencing proteins in cell signaling pathways. | ||||||